CellSource Co

CellSource Co Operating Cash Flow

The Operating Cash Flow of CellSource Co (4880.T) as of Oct 28, 2026 is 333.10 M JPY. In the previous year, Operating Cash Flow was 591.72 M JPY — a change of -43.71% (lower).

Operating Cash Flow

333.10 MJPY

YoY

-43.71%

Last updated:

Operating Cash Flow of CellSource Co is 2025 333.10 M JPY. Operating Cash Flow of CellSource Co was 2024 591.72 M JPY. It decreases by -43.71% lower compared to the previous year.

The CellSource Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
213.97 M JPY
Jan 1, 2019
195.29 M JPY
Jan 1, 2020
330.23 M JPY
Jan 1, 2021
898.19 M JPY
Jan 1, 2022
847.60 M JPY
Jan 1, 2023
846.69 M JPY
Jan 1, 2024
591.72 M JPY
Jan 1, 2025
333.10 M JPY
The CellSource Co Operating Cash Flow history
YEAROperating Cash FlowYoY
333.10 MJPY-43.71%
591.72 MJPY-30.11%
846.69 MJPY-0.11%
847.60 MJPY-5.63%
898.19 MJPY+171.99%
330.23 MJPY+69.10%
195.29 MJPY-8.73%
213.97 MJPY+94.62%
109.94 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Operating Cash Flow of CellSource Co is 333.10 M JPY in 2025.

Operating Cash Flow of CellSource Co changed from 591.72 M JPY to 333.10 M JPY, representing a -43.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSource Co

All Key Metrics — CellSource Co